$TPST
Tempest Therapeutics, Inc. Stock $tpst

$tpst Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-Q Financial Statement

#000154422717000010 Filed on August 03, 2017

Income Statement

Concept	2017 Q3	2017 Q2	2016 Q2
Revenue	$56.00K	$84.00K	$189.0K
YoY Change	-71.57%	-55.56%	530.0%
Cost Of Revenue	$29.00K	$274.0K	$1.233M
YoY Change	-98.14%	-77.78%	962.93%
Gross Profit	$27.00K	-$190.0K	-$1.044M
YoY Change	-101.98%	-81.8%	1113.95%
Gross Profit Margin	48.21%	-226.19%	-552.38%
Selling, General & Admin	$5.056M	$10.75M	$11.21M
YoY Change	-59.91%	-4.09%	-14.21%
% of Gross Profit	18725.93%
Research & Development	$4.016M	$4.997M	$5.987M
YoY Change	-19.52%	-16.54%	48.89%
% of Gross Profit	14874.07%
Depreciation & Amortization	$400.0K	$500.0K	$600.0K
YoY Change	-33.33%	-16.67%	200.0%
% of Gross Profit	1481.48%
Operating Expenses	$9.462M	$18.01M	$18.43M
YoY Change	-50.62%	-2.26%	7.13%
Operating Profit	-$9.406M	-$17.93M	-$18.24M
YoY Change	-50.4%	-1.7%	6.21%
Interest Expense	$50.00K	-$270.0K	-$260.0K
YoY Change	-125.0%	3.85%	-10.34%
% of Operating Profit
Other Income/Expense, Net	-$3.000K	$25.00K	-$22.00K
YoY Change	-90.91%	-213.64%	-21.43%
Pretax Income	-$9.356M	-$18.17M	-$18.52M
YoY Change	-51.27%	-1.86%	5.88%
Income Tax	$11.00K	$13.00K	$50.00K
% Of Pretax Income
Net Earnings	-$9.367M	-$18.19M	-$18.57M
YoY Change	-51.44%	-2.06%	6.16%
Net Earnings / Revenue	-16726.79%	-21650.0%	-9824.34%
Basic Earnings Per Share
Diluted Earnings Per Share	-$58.56	-$113.70	-$142.80
COMMON SHARES
Basic Shares Outstanding	35.69M shares	35.66M shares	27.33M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q3	2017 Q2	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$75.70M	$86.60M	$147.7M
YoY Change	-42.21%	-41.37%	-5.08%
Cash & Equivalents	$24.78M	$22.94M	$95.89M
Short-Term Investments	$51.00M	$63.60M	$51.80M
Other Short-Term Assets	$1.900M	$2.500M	$2.500M
YoY Change	-24.0%	0.0%	-28.57%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$77.61M	$89.09M	$150.1M
YoY Change	-41.85%	-40.65%	-5.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.606M	$3.956M	$8.149M
YoY Change	-55.19%	-51.45%	93.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00
YoY Change	-100.0%
Other Assets	$23.00K	$23.00K	$23.00K
YoY Change	0.0%	0.0%
Total Long-Term Assets	$4.418M	$4.791M	$8.611M
YoY Change	-50.6%	-44.36%	62.72%
TOTAL ASSETS
Total Short-Term Assets	$77.61M	$89.09M	$150.1M
Total Long-Term Assets	$4.418M	$4.791M	$8.611M
Total Assets	$82.03M	$93.89M	$158.7M
YoY Change	-42.4%	-40.85%	-3.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.691M	$3.275M	$2.466M
YoY Change	-2.85%	32.81%	-17.44%
Accrued Expenses	$6.212M	$9.000K	$8.300M
YoY Change	-26.92%	-99.89%	80.43%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.903M	$11.82M	$10.74M
YoY Change	-20.97%	10.05%	41.35%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$834.0K	$925.0K	$1.400M
YoY Change	-35.85%	-33.93%	839.6%
Total Long-Term Liabilities	$834.0K	$925.0K	$1.400M
YoY Change	-35.85%	-33.93%	839.6%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.903M	$11.82M	$10.74M
Total Long-Term Liabilities	$834.0K	$925.0K	$1.400M
Total Liabilities	$9.737M	$12.74M	$12.17M
YoY Change	-22.23%	4.76%	57.03%
SHAREHOLDERS EQUITY
Retained Earnings	-$293.0M	-$283.6M	-$208.2M
YoY Change	28.75%	36.19%	60.94%
Common Stock	$36.00K	$36.00K	$36.00K
YoY Change	0.0%	0.0%	33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$72.29M	$81.14M	$146.6M
YoY Change
Total Liabilities & Shareholders Equity	$82.03M	$93.89M	$158.7M
YoY Change	-42.4%	-40.85%	-3.49%

Cashflow Statement

Concept	2017 Q3	2017 Q2	2016 Q2
OPERATING ACTIVITIES
Net Income	-$9.367M	-$18.19M	-$18.57M
YoY Change	-51.44%	-2.06%	6.16%
Depreciation, Depletion And Amortization	$400.0K	$500.0K	$600.0K
YoY Change	-33.33%	-16.67%	200.0%
Cash From Operating Activities	-$10.30M	-$12.09M	-$15.92M
YoY Change	-33.29%	-24.06%	32.01%
INVESTING ACTIVITIES
Capital Expenditures	$10.00K	$20.00K	$500.0K
YoY Change	-94.44%	-96.0%	-34.21%
Acquisitions
YoY Change
Other Investing Activities	$11.78M	$10.00M	$37.78M
YoY Change	-139.4%	-73.53%	-172.25%
Cash From Investing Activities	$11.76M	$9.970M	$37.28M
YoY Change	-139.11%	-73.26%	-170.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$53.90M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	54.06M
YoY Change	-100.0%	-100.0%	8346.87%
NET CHANGE
Cash From Operating Activities	-10.30M	-12.09M	-15.92M
Cash From Investing Activities	11.76M	9.970M	37.28M
Cash From Financing Activities	0.000	0.000	54.06M
Net Change In Cash	1.460M	-2.120M	75.42M
YoY Change	-103.22%	-102.81%	-216.98%
FREE CASH FLOW
Cash From Operating Activities	-$10.30M	-$12.09M	-$15.92M
Capital Expenditures	$10.00K	$20.00K	$500.0K
Free Cash Flow	-$10.31M	-$12.11M	-$16.42M
YoY Change	-33.99%	-26.25%	28.08%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Type DocumentType	10-Q
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	373000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	335000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Period End Date DocumentPeriodEndDate	2017-06-30
	dei	Entity Central Index Key EntityCentralIndexKey	0001544227
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	35686489	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	OvaScience, Inc.
CY2016Q4	ovas	Accrued Legal Audit And Tax Services Current AccruedLegalAuditAndTaxServicesCurrent	1000	USD
CY2017Q2	ovas	Accrued Legal Audit And Tax Services Current AccruedLegalAuditAndTaxServicesCurrent	1000	USD
CY2016Q4	ovas	Accrued Professional And Consultant Fees Current AccruedProfessionalAndConsultantFeesCurrent	1000	USD
CY2017Q2	ovas	Accrued Professional And Consultant Fees Current AccruedProfessionalAndConsultantFeesCurrent	0	USD
CY2016Q4	ovas	Development Site Costs And Contract Manufacturing DevelopmentSiteCostsAndContractManufacturing	1000	USD
CY2017Q2	ovas	Development Site Costs And Contract Manufacturing DevelopmentSiteCostsAndContractManufacturing	0	USD
CY2013Q4	ovas	Ownership Control Percentage With Disputes Resolved Through Arbitration OwnershipControlPercentageWithDisputesResolvedThroughArbitration	0.5
	ovas	Proceeds From Issuance Of Common Stock From Share Based Compensation Plan Net Of Tax ProceedsFromIssuanceOfCommonStockFromShareBasedCompensationPlanNetOfTax	111000	USD
	ovas	Proceeds From Issuance Of Common Stock From Share Based Compensation Plan Net Of Tax ProceedsFromIssuanceOfCommonStockFromShareBasedCompensationPlanNetOfTax	0	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2183000	USD
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3275000	USD
CY2016Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	11026000	USD
CY2017Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	8544000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11000	USD
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3428000	USD
CY2017Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3917000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-60000	USD
CY2017Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-49000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	358419000	USD
CY2017Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	364739000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	498000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	91000	USD
CY2016Q4	us-gaap	Assets Assets	122543000	USD
CY2017Q2	us-gaap	Assets Assets	93885000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	116444000	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	89094000	USD
CY2017Q2	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	500000	USD
CY2017Q1	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	500000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	114388000	USD
CY2017Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	86559000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3000	USD
CY2017Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	63000	USD
CY2017Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	49000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	114448000	USD
CY2017Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	86608000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	46600000	USD
CY2017Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	46400000	USD
CY2016Q4	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	21	security
CY2017Q2	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	17	security
CY2017Q2	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	17	security
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43224000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	95894000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43930000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22937000	USD
CY2017Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	86600000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35641505	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35686489	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35641505	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35686489	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	36000	USD
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	36000	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18552000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-40147000	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18176000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33070000	USD
CY2016Q2	us-gaap	Cost Of Revenue CostOfRevenue	1233000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	2409000	USD
CY2017Q2	us-gaap	Cost Of Revenue CostOfRevenue	274000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	543000	USD
CY2017Q2	us-gaap	Deferred Compensation Arrangement With Individual Cash Award Granted Amount DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount	800000	USD
	us-gaap	Deferred Compensation Arrangement With Individual Requisite Service Period1 DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1	P1Y6M
CY2016Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	600000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1067000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1100000	USD
CY2017Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	500000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	951000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1000000	USD
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.62
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.41
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.51
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.93
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6000	USD
CY2017Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5000	USD
CY2013Q4	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	1500000	USD
CY2013Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.5
CY2016Q4	us-gaap	Equity Method Investments EquityMethodInvestments	65000	USD
CY2017Q2	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	USD
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	250000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1208000	USD
CY2016Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	161000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3425000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-544000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	29000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-197000	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18518000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-40201000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18173000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-33059000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-807000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-875000	USD
CY2016Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	50000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	125000	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-921000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1101000	USD
CY2017Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	186000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	368000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	77000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	74000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	14325000	USD
CY2017Q2	us-gaap	Liabilities Liabilities	12744000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	122543000	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	93885000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13209000	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	11819000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	52670000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-20993000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	54060000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	29939000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6282000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-31329000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27275000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-18568000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-40326000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-18186000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-33081000	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	18430000	USD
	us-gaap	Operating Expenses OperatingExpenses	40015000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	18014000	USD
	us-gaap	Operating Expenses OperatingExpenses	32664000	USD
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	750000	USD
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	800000	USD
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	0	USD
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	868000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	101000	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	25000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-35000	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	4110000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-18241000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-39680000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-17930000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-32517000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2000	USD
CY2017Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23000	USD
CY2017Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	16000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	179000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	10000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	11000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1116000	USD
CY2017Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	925000	USD
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-22000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-49000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	27142000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	43476000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2056000	USD
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2535000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	53949000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	35413000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	50232000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	23089000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9000000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7873000	USD
	us-gaap	Revenues Revenues	335000	USD
CY2017Q2	us-gaap	Revenues Revenues	84000	USD
	us-gaap	Revenues Revenues	147000	USD
CY2016Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11210000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5572000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3956000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5987000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11942000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4997000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10761000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	439000	USD
CY2017Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	812000	USD
CY2017Q2	us-gaap	Restructuring And Related Cost Cost Incurred To Date1 RestructuringAndRelatedCostCostIncurredToDate1	8900000	USD
CY2016Q2	us-gaap	Restructuring Charges RestructuringCharges	0	USD
	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2017Q2	us-gaap	Restructuring Charges RestructuringCharges	1992000	USD
CY2017Q2	us-gaap	Restructuring Charges RestructuringCharges	2000000	USD
	us-gaap	Restructuring Charges RestructuringCharges	3480000	USD
	us-gaap	Restructuring Charges RestructuringCharges	3500000	USD
CY2016Q4	us-gaap	Restructuring Reserve RestructuringReserve	3406000	USD
CY2017Q2	us-gaap	Restructuring Reserve RestructuringReserve	2467000	USD
CY2017Q2	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	2500000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-250177000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-283585000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-283600000	USD
CY2016Q2	us-gaap	Revenues Revenues	189000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	25664000	USD
CY2017Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10751000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	17880000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5717000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5918000	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.28
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.27
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.11
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.15
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	446450	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1487100	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2183106	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4015356	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.32
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.48
CY2017Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.46
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.51
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	70458000	USD
CY2017Q2	us-gaap	Short Term Investments ShortTermInvestments	63622000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	108218000	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	81141000	USD
CY2017Q2	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	300000	USD
	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	0.5
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30036000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28668000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35664000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35653000	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of estimates and summary of significant accounting policies</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These condensed consolidated financial statements are presented in conformity with GAAP, which requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our significant accounting policies are described in Note 2, “Summary of Significant Accounting Policies,” in our 2016 Annual Report on Form 10-K.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the first quarter of 2017, we adopted Accounting Standard Update (ASU) ASU 2016-09 Compensation - Stock Based Compensation and have changed our accounting policy regarding the accounting for forfeitures and have elected to account for forfeitures as they occur. We adopted ASU 2016-09, using a modified retrospective approach and recorded a cumulative catch-up to retained earnings of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div></div>

Files In Submission

Name	View Source	Status
R34.htm	Edgar Link	pending
0001544227-17-000010-index-headers.html	Edgar Link	pending
0001544227-17-000010-index.html	Edgar Link	pending
0001544227-17-000010.txt	Edgar Link	pending
0001544227-17-000010-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ovas-20170630.xml	Edgar Link	completed
ovas-20170630.xsd	Edgar Link	pending
ovas-20170630x10q.htm	Edgar Link	pending
ovas-20170630xex101.htm	Edgar Link	pending
ovas-20170630xex102.htm	Edgar Link	pending
ovas-20170630xex103.htm	Edgar Link	pending
ovas-20170630xex104.htm	Edgar Link	pending
ovas-20170630xex311.htm	Edgar Link	pending
ovas-20170630xex312.htm	Edgar Link	pending
ovas-20170630xex321.htm	Edgar Link	pending
ovas-20170630xex322.htm	Edgar Link	pending
ovas-20170630_cal.xml	Edgar Link	unprocessable
ovas-20170630_def.xml	Edgar Link	unprocessable
ovas-20170630_lab.xml	Edgar Link	unprocessable
ovas-20170630_pre.xml	Edgar Link	unprocessable
ovasexhibit1012017q21_image1.jpg	Edgar Link	pending
ovasexhibit1022017q21_image1.jpg	Edgar Link	pending
ovasexhibit1032017q21_image1.jpg	Edgar Link	pending
ovasexhibit1042017q21_image1.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TPST
Tempest Therapeutics, Inc. Stock $tpst

2017 Q3 Form 10-Q Financial Statement

#000154422717000010 Filed on August 03, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST Tempest Therapeutics, Inc. Stock $tpst

2017 Q3 Form 10-Q Financial Statement

#000154422717000010 Filed on August 03, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST
Tempest Therapeutics, Inc. Stock $tpst